Phreesia (NYSE:PHR) Receives Market Perform Rating from Citizens Jmp

Phreesia (NYSE:PHR)‘s stock had its “market perform” rating reissued by Citizens Jmp in a research note issued to investors on Wednesday.

Other analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Phreesia from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 8th. Mizuho cut their price target on Phreesia from $22.00 to $19.00 and set an “outperform” rating for the company in a report on Tuesday, March 24th. Barclays reduced their price target on Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 16th. Canaccord Genuity Group decreased their price objective on Phreesia from $33.00 to $22.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Zacks Research lowered Phreesia from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Twelve research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Phreesia currently has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Phreesia Price Performance

NYSE:PHR opened at $8.33 on Wednesday. The firm has a market cap of $502.28 million, a price-to-earnings ratio of 277.70 and a beta of 0.67. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average is $12.36 and its two-hundred day moving average is $17.57. Phreesia has a 12-month low of $7.77 and a 12-month high of $32.76.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). The firm had revenue of $127.07 million for the quarter, compared to analysts’ expectations of $126.75 million. Phreesia had a return on equity of 3.33% and a net margin of 0.48%.The business’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.11) earnings per share. Research analysts expect that Phreesia will post -1.1 EPS for the current year.

Insider Activity at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 6,176 shares of the company’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $11.97, for a total transaction of $73,926.72. Following the completion of the sale, the general counsel directly owned 163,485 shares in the company, valued at $1,956,915.45. This represents a 3.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Amy Beth Vanduyn sold 2,202 shares of the firm’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $16.36, for a total value of $36,024.72. Following the completion of the transaction, the senior vice president owned 157,349 shares in the company, valued at approximately $2,574,229.64. This trade represents a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 70,358 shares of company stock valued at $1,123,569 over the last three months. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada grew its stake in shares of Phreesia by 208.8% in the first quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock valued at $617,000 after buying an additional 16,309 shares in the last quarter. AQR Capital Management LLC lifted its position in Phreesia by 471.2% during the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after acquiring an additional 132,015 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Phreesia by 3.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after acquiring an additional 2,158 shares in the last quarter. NewEdge Advisors LLC boosted its holdings in Phreesia by 262.7% in the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock worth $395,000 after acquiring an additional 11,181 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in Phreesia by 0.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock worth $15,336,000 after acquiring an additional 2,402 shares during the period. 92.10% of the stock is owned by institutional investors and hedge funds.

Phreesia News Summary

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Company reached profitability and strong cash‑flow milestones (positive GAAP net income, +$78.8M operating cash, >$50M free cash flow, and >$100M adjusted EBITDA) alongside ~16% y/y revenue growth, supporting a longer‑term recovery thesis. Business Wire: Q4 results
• Positive Sentiment: Some shop-side analysts kept constructive ratings (e.g., Stephens remains overweight with a $20 PT; other firms maintain buy/outperform stances despite lower targets), signaling pockets of analyst support for a rebound. Benzinga: analyst actions
• Neutral Sentiment: Full earnings and call transcripts are available for investors digging into management commentary and the detail behind the guide cut (useful for assessing timing of client spend recovery). Earnings call transcript
• Negative Sentiment: Phreesia cut FY27 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker-than-expected second‑half commitments; this is the primary catalyst for the selloff. Benzinga: guidance cut
• Negative Sentiment: Investors punished the stock after the quarter: reported EPS missed one set of consensus estimates (and media reported a sharp post‑earnings decline), triggering heavy selling and headlines about a ~25–30% intraday drop. Investing.com: shares tumble
• Negative Sentiment: Multiple firms lowered price targets and re-priced risk: examples include JPMorgan ($16 PT), BMO ($14), Needham ($14), Canaccord ($22), Truist ($11), Robert W. Baird and Citi (both $10), increasing near‑term analyst uncertainty. Benzinga: analyst PT cuts

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.